Long-term safety of MY008211A for PNH
Treatments studied
Part of Blood & lymphatic clinical trials.
This study checks the long-term safety of the drug MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH). It is only for those who already took the drug in an earlier study and had benefit, and who have had specific vaccines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already completed a prior study of the drug MY008211A and your doctor believes you benefited.
- You need to have had vaccines for certain bacteria: meningococcus, pneumococcus, and Haemophilus influenzae.
- You cannot have had repeated serious infections from those bacteria in the past.
- You cannot have a known or suspected inherited problem with your complement immune system.
- You cannot have an active infection or cancer that might increase risks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called VSA012 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. The goal is to see if VSA012 can help manage symptoms like fatigue and low blood counts better than the current standard treatment.
This study tests an oral medication (MY008211A) designed to reduce red blood cell destruction in people with paroxysmal nocturnal hemoglobinuria (PNH). The trial aims to see if the drug is safe and effective in improving anemia and lowering markers of disease activity.
This early-stage study tests how safe and tolerable ADX-038 is, and how the body processes it, in healthy volunteers and in people with paroxysmal nocturnal hemoglobinuria (PNH). It may help researchers understand whether the drug works safely for PNH patients and identify the right dosing.
This study tests an investigational oral medication called TUL321 in healthy volunteers to see if it is safe and how the body handles it. It may help understand the drug's effects and is an early step in developing a new treatment.
This study tests a new medicine called SLN12140 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It aims to see if the drug can help manage the disease and improve symptoms.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria (PNH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.